So there is a need to develop a new index that can distinguish minimal fibrosis (F0-F1) from significant (F2-F4) and advanced (F2-F3) from cirrhosis (F4). While considering substantial ...

F0 – no fibrosis F1 – mild fibrosis F2 – moderate fibrosis F3 – advanced fibrosis F4 – cirrhosis. People with advanced fibrosis or cirrhosis are at higher risk of developing a type of liver cancer ...

The adjustment of the price target comes in the wake of promising Phase IIB trial results for Akero's treatment for NASH (non-alcoholic steatohepatitis), particularly in patients with F4 cirrhosis.

Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals with biopsy-confirmed compensated cirrhosis (F4), Child ...

Activity (necroinflammation) and fibrosis are two major histologic features of chronic hepatitis C included in different proposed classifications. One of the few validated scoring systems is ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed ...